Minor Cannabinoid Rise in EU (HHC, THCP and more)

an ai painting depicting Josep Borrel and art enthusiasts gathered around in admiration

In recent years, there has been a substantial surge in interest in and usage of minor cannabinoids in the European Union (EU). While THC and CBD are certainly the most well-known cannabinoids, attention is turning to lesser-known substances such as CBN, CBG, HHC, THCV, and THCP. These minor cannabinoids provide distinct advantages and qualities, and they are gaining popularity as beneficial additives in a variety of goods. In this blog article, we will look at the properties of these minor cannabinoids, their prospective uses, and how they are influencing the cannabis sector in the EU.

Most popular minor cannabinoids:

Cannabinol (CBN) is a moderately psychoactive cannabinoid produced when THC is exposed to air and heat. While the prominence of THC and CBD has partly eclipsed CBN, current study has revealed its potential medicinal advantages. CBN has been found in studies to have the potential to be a sleep aid, anti-inflammatory, antimicrobial, and hunger stimulant. As a result, it is increasingly being employed in products that attempt to improve sleep quality and general wellbeing.

Cannabigerol (CBG) is a non-psychoactive cannabinoid known as the "mother of all cannabinoids." This is due to the fact that CBG is the precursor of THC, CBD, and other cannabinoids. It has attracted interest due to its potential medicinal qualities, which include anti-inflammatory, antimicrobial, and neuroprotective activities. CBG is currently being used in a variety of products, including topical creams, tinctures, and supplements, to treat skin disorders and to manage pain.

Hexahydrocannabinol (HHC) is a newcomer to the cannabis market. It is a THC that has been hydrogenated, resulting in a molecule with a similar chemical structure but somewhat different effects. According to preliminary study, HHC may have potential medicinal advantages such as anti-inflammatory and analgesic characteristics without generating the same euphoric effects as THC. As research into HHC continues, it is anticipated that it will become a more significant element in various cannabis products.

Tetrahydrocannabivarin (THCV) is a minor cannabinoid with a structure similar to THC but distinct characteristics. Unlike THC, which has been demonstrated to stimulate hunger, THCV is known to suppress appetite. It may also have anticonvulsant, anti-inflammatory, and blood sugar-regulating properties. THCV is utilized in products for weight loss and metabolic health, as well as those for treating symptoms of illnesses including epilepsy and diabetes.

Tetrahydrocannabiphorol (THCP) is a new cannabinoid with a similar structure to THC but a longer chemical tail. According to preliminary study, THCP may have a higher affinity for the CB1 receptor in the human body, perhaps leading to greater psychoactive effects. Although research on THCP is still in its early stages, its distinct features have piqued the curiosity of the cannabis community.

Current situation 

The rising awareness of cannabis's potential medicinal advantages, as well as interest in regulating and taxing recreational use, is driving a trend toward relaxed or revised cannabis regulation across Europe. Medical cannabis programs have grown in Germany, Italy, and the Netherlands, allowing patients with a variety of ailments to obtain cannabis medicines under medical supervision.

Furthermore, countries like as Spain, Portugal, and Switzerland have implemented more liberal regulations regarding recreational cannabis use, and several countries are exploring pilot projects or legal reforms to investigate the potential advantages of a regulated recreational cannabis industry. Shifting public opinion, potential tax income, and the desire to lessen negative consequences connected with the illicit cannabis industry are all factors leading to these legislative reforms. As more European countries evaluate their laws and witness legalization attempts in other regions, the trend toward progressive cannabis legislation is projected to continue.

Germany to the rescue?

According to The Guardian, Germany's health minister, Karl Lauterbach, unveiled a new two-phase plan to legalize recreational cannabis by the end of the year, noting the failure of past cannabis laws. The first step involves the formation of "cannabis social clubs" with a membership limit of 500 people, with membership restricted to German residents. Adults aged 21 and older can receive up to 25g of cannabis per day and up to 50g per month from these clubs, while those aged 18-21 can only obtain 30g per month. Consumption will be forbidden on club grounds. Adults will also be permitted to grow up to three female blooming plants at home for leisure purposes.

Under a five-year pilot program, the second phase allows chosen towns and municipalities across Germany to license "specialist shops" to sell recreational cannabis. This concept is inspired by comparable initiatives in other US states and Canada.


The growing interest in minor cannabinoids like CBN, CBG, HHC, THCV, and THCP is transforming the European cannabis business, which EU member states cannot ignore and encourages an even more rapid and planned regulatory approach to hemp goods. CBD, for example, has been known for years in the European area but is still not approved as a dietary supplement despite extensive study and monitoring. This trend is still going on today, with EU commissions declaring that each of the new cannabinoids has to be explored deeper in order to figure out why there is so much interest. According to Google search request statistics, the majority of searches for cannabis alternatives occur in areas where THC products are illegal. EU commission, let us save you some time, as it is already obvious that  the apparent solution to the looming interest in minor cannabinoids is legalization of cannabis.